Japanese Renewable Energy Stock News

Japan Post Insurance has now completed the share repurchase program announced on November 14, 2025, buying back 10,216,800 shares, or 2.77% of its outstanding stock, for ¥44,999.71 million by March 24, 2026. This completed buyback meaningfully reduces the share count and highlights the company’s recent focus on returning surplus capital to shareholders. We’ll now examine how the completed buyback program, and its impact on share count, may influence Japan Post Insurance’s investment...

If you are wondering whether Kioxia Holdings is priced for perfection or still offers value, the recent share price is giving plenty to think about. The stock closed at ¥19,965 after a very large 1 year return of around 7x, even though the last 7 days and 30 days show 7.0% and 5.9% declines and the year to date gain sits at 75.9%. Recent coverage has circled around Kioxia's position in the semiconductor supply chain and its exposure to memory demand, with investors weighing how those themes...

If you are wondering whether Fuji Electric's current share price really reflects the underlying business, the next sections break down what the numbers are actually saying about value. The stock last closed at ¥10,810, with returns of 2.9% over 7 days, a 22.3% decline over 30 days, a 10.6% decline year to date, and gains of 73.3% over 1 year, 113.7% over 3 years, and 151.7% over 5 years. This gives plenty for valuation minded investors to think about. Recent coverage has focused on Fuji...

Board meeting focus and why it matters for Ito En shareholders Ito En (TSE:2593) has called a board meeting for March 27, 2026 to review the establishment of a new subsidiary via a company split, a structural move that naturally puts the share price under the microscope for investors. See our latest analysis for Ito En. The upcoming company split decision comes after a mixed price pattern, with a 6.44% 7 day share price return contrasting with a 2.62% 30 day decline and a 53.29% 5 year total...

As global markets navigate the complexities of Middle East conflicts and energy price volatility, investor sentiment remains cautious amid mixed performances across major indices. In this environment, identifying undervalued stocks—those trading below their intrinsic value—can offer potential opportunities for investors seeking resilience against geopolitical and economic uncertainties.

Eisai and its partners recently reported real-world data at the AD/PD 2026 conference showing that most early Alzheimer’s patients in the U.S. remained on intravenous lecanemab beyond 18 months, with persistence still above two-thirds at 24 months, broadly aligning with outcomes seen in the Phase 3 Clarity AD trial and its long-term extension. The new findings, alongside expanding approvals and filings for more convenient maintenance and subcutaneous lecanemab dosing, reinforce the therapy’s...

The Asian markets have been navigating a complex landscape marked by energy price volatility and geopolitical tensions, with these factors significantly influencing investor sentiment and economic outlooks across the region. Amidst this backdrop, high growth tech stocks in Asia are drawing attention for their potential to offer robust returns despite broader market uncertainties. In such an environment, a good stock is often characterized by strong fundamentals, resilience to external shocks...

In March 2026, J. Front Retailing Co., Ltd. reported that its consolidated sales for February rose 13.2%, with year‑to‑date sales up 3.2%. This acceleration in monthly and year‑to‑date sales offers a fresh data point on how the group’s renovation, inbound and content initiatives may be resonating with customers. With February’s strong 13.2% consolidated sales growth as a backdrop, we’ll now examine how this update influences J. Front Retailing’s investment narrative. Invest in the nuclear...

In March 2026, T&D Holdings, Inc. raised its fiscal 2026 ordinary revenue forecast to ¥3.42 trillion and lifted expected earnings per share to ¥237.45, citing stronger-than-anticipated insurance premium income from higher sales of single premium products, while leaving profit guidance unchanged. The company also increased its year-end dividend guidance to ¥68 per share and introduced a new policy targeting cash dividends of about 60% of five-year average Group adjusted profit, signaling a...

Board meeting puts Kanadevia’s group structure in focus Kanadevia (TSE:7004) has called a board meeting for March 26, 2026, to review and approve a potential share transfer involving a consolidated subsidiary, bringing attention to how any change might affect the wider group. See our latest analysis for Kanadevia. The upcoming board meeting lands after a mixed period for the stock, with a 7.92% year to date share price return and a 10.11% one year total shareholder return suggesting that...

Amidst a backdrop of geopolitical tensions and fluctuating energy prices, Asian markets are navigating a complex landscape that influences investor sentiment. In this environment, dividend stocks can offer stability and potential income, making them an attractive option for those seeking to balance risk with consistent returns.

Daiichi Sankyo Company (TSE:4568) shares are in focus after a new collaboration with Tempus AI to apply foundation models and real-world oncology data to an antibody drug conjugate program. See our latest analysis for Daiichi Sankyo Company. The AI collaborations, ENHERTU approval in Japan and completion of the latest buyback tranche come as the share price trades at ¥2,930 following a 1 day share price return of 1.93%. However, the 1 year total shareholder return of 19.20% and 3 year total...

Takeda Pharmaceutical (TSE:4502) is back in focus after releasing new Phase 3 data for its investigational TYK2 inhibitor zasocitinib in moderate to severe plaque psoriasis, paired with plans for future regulatory filings. See our latest analysis for Takeda Pharmaceutical. The zasocitinib data appear to have arrived during a strong run for the shares, with a 90-day share price return of 19.92% and a 1-year total shareholder return of 33.75% suggesting momentum has been building over both...

Sojitz group company Royal Healthcare in Singapore has begun offering NEC Corporation's FonesVisuas Test, an advanced blood test that estimates the risk of multiple diseases. This marks Sojitz's entry into predictive health testing in Southeast Asia through its partnership with NEC and Royal Healthcare. The move expands Sojitz's presence in healthcare, adding a new dimension to its business portfolio in the Asia Pacific region. For investors tracking Sojitz (TSE:2768), this development adds...

Elliott Investment Management’s new statement on Mitsui O.S.K. Lines (TSE:9104) has pushed investor attention toward the company’s upcoming medium term management plan and the question of how the market values its shipping assets. See our latest analysis for Mitsui O.S.K. Lines. The Elliott statement lands after a strong run in the share price, with a 30 day share price return of 23.39% and a 90 day share price return of 51.93%. The 5 year total shareholder return of roughly 7x signals that...

Why Tokyo Electron Is On Investors’ Radar Now Tokyo Electron (TSE:8035) has drawn attention after a sharp month pullback of about 13%, even as its past 3 months return sits around 14%. That gap is prompting closer scrutiny from investors. See our latest analysis for Tokyo Electron. The recent 13% one-month share price pullback to about ¥39,290 comes after a 14% three-month share price return and a very strong one-year total shareholder return of 84%. This suggests that short-term momentum has...

Wondering whether Nintendo's share price reflects its true value today, or if the market is missing something that you could be early to? The stock recently closed at ¥9,215, with a 5.5% gain over the last 30 days, although returns sit at a 13.5% decline year to date and a 14.7% decline over the last year, set against an 87.7% gain over 3 years and 63.7% over 5 years. Recent coverage has focused on how Nintendo fits into the broader entertainment and gaming sector, including discussion of...

Investors in Kao Corporation ( TSE:4452 ) had a good week, as its shares rose 2.2% to close at JP¥6,147 following the...

On March 18, 2026, Toho Co., Ltd.’s board approved sweeping leadership changes, including Representative Director Yoshishige Shimatani stepping down to become Corporate Adviser and the planned retirement of several senior Executive Officers across its real estate, theatrical, and cinema businesses. These shifts reshuffle decision‑making power across Toho’s core operating groups, potentially signaling an internal rethink of how its film, theater, and property operations are led. With these...

Rohto PharmaceuticalLtd (TSE:4527) has announced a share repurchase program, authorizing the buyback of up to 1,500,000 shares for ¥3,000 million. The initiative is intended to improve capital efficiency and support flexible capital policies. See our latest analysis for Rohto PharmaceuticalLtd. At a share price of ¥2,412.0, Rohto PharmaceuticalLtd has a 7 day share price return of 2.14% and a 1 year total shareholder return of 6.88%. The 3 year total shareholder return of 10.34% contrasts...

Recent share performance context Kioxia Holdings (TSE:285A) has drawn attention after a sharp share price swing, with the stock showing a 4.2% decline over the past day and a 9.3% drop over the past week. See our latest analysis for Kioxia Holdings. Despite the recent pullback, with a 5.6% 1 month share price return decline, Kioxia Holdings still shows strong momentum when viewed over the year, highlighted by a 77.6% 3 month share price return and a very large 1 year total shareholder...

Event context and recent share performance Honda Motor (TSE:7267) has been drawing attention after recent share price swings, with the stock up around 1.5% over the past day but showing weaker performance over the past month and past 3 months. For investors, that mix of short term strength and recent declines raises questions about how current expectations around earnings, cash flows, and long term demand for Honda’s automobiles, motorcycles, and power products are being reflected in the...

Hokuriku Electric Power (TSE:9505) cut its profit outlook for the year ending March 31, 2026, after deciding to abolish the Fukui Thermal Power Station Mikuni Unit 1 and recognize related impairment losses. See our latest analysis for Hokuriku Electric Power. The board’s decision on Mikuni Unit 1 and the resulting downgrade to profit guidance comes against a backdrop of a 13.31% 90 day share price return and a 94.79% 3 year total shareholder return. This suggests recent momentum has built on...

Ono Pharmaceutical has submitted a manufacturing and marketing application in Japan for ripretinib, an oral tyrosine kinase inhibitor for advanced gastrointestinal stromal tumor that has progressed after prior chemotherapy, supported by positive global Phase 3 INVICTUS data showing significantly prolonged progression-free survival versus placebo. The filing is reinforced by ripretinib’s orphan drug status and its designation as a high medical-need therapy in Japan, highlighting its potential...